Rethinking Hypothyroidism: Why Treatment Must Change and What Patients Can Do

· University of Chicago Press · āļšāļĢāļĢāļĒāļēāļĒāđ‚āļ”āļĒāđ€āļŠāļĩāļĒāļ‡ AI āļ‚āļ­āļ‡ Mason (āļˆāļēāļ Google)
3.0
1 āļĢāļĩāļ§āļīāļ§
āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļŠāļĩāļĒāļ‡
8 āļŠāļĄ. 8 āļ™āļēāļ—āļĩ
āļ‰āļšāļąāļšāļŠāļĄāļšāļđāļĢāļ“āđŒ
āļšāļĢāļĢāļĒāļēāļĒāđ‚āļ”āļĒ AI
āļ„āļ°āđāļ™āļ™āđāļĨāļ°āļĢāļĩāļ§āļīāļ§āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļāļēāļĢāļ•āļĢāļ§āļˆāļŠāļ­āļšāļĒāļ·āļ™āļĒāļąāļ™  āļ”āļđāļ‚āđ‰āļ­āļĄāļđāļĨāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŸāļąāļ‡āļ•āļąāļ§āļ­āļĒāđˆāļēāļ‡āļĢāļ°āļĒāļ°āđ€āļ§āļĨāļē 5 āļ™āļēāļ—āļĩ āđ„āļ”āđ‰āļ—āļļāļāđ€āļĄāļ·āđˆāļ­āđāļĄāđ‰āļ‚āļ“āļ°āļ­āļ­āļŸāđ„āļĨāļ™āđŒÂ 
āđ€āļžāļīāđˆāļĄ

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļŠāļĩāļĒāļ‡āđ€āļĨāđˆāļĄāļ™āļĩāđ‰

In this primer for patients, their families, and their doctors, a leading physician and scientist explains why the standard treatment for hypothyroidism fails many—and offers an empowering call for change.


Hypothyroidism, also commonly referred to as Hashimoto’s disease, affects millions in the United States alone. It occurs when the thyroid—the butterfly-shaped gland that sits in your neck right above the front of your shirt collar—malfunctions or after thyroid surgery, causing thyroid hormone levels in circulation to drop below normal. Thus, treatment is aimed at bringing these hormone levels back to normal. This is done with daily tablets of thyroxine or T4. Because hypothyroidism is so common, we likely know someone who is on this type of medication. While most patients respond well to this standard treatment, about ten to twenty percent (some two to three million individuals in the United States) are far from living a typical life. They exhibit “foggy brain”—low energy, confusion, and poor memory. Many doctors have shrugged off their complaints, believing these symptoms to be unrelated to the thyroid disease. In Rethinking Hypothyroidism, Dr. Antonio C. Bianco, a physician and a scientist who has studied hypothyroidism and thyroid hormones for decades, offers an accessible overview of the disease’s treatment and the role of big pharma in shaping it, making the case that the current approach is failing many patients. But more than this, Bianco calls for alternatives to improve lives, and he equips patients and their families with the tools to advocate for other treatments.

āļāļēāļĢāđƒāļŦāđ‰āļ„āļ°āđāļ™āļ™āđāļĨāļ°āļĢāļĩāļ§āļīāļ§

3.0
1 āļĢāļĩāļ§āļīāļ§

āđ€āļāļĩāđˆāļĒāļ§āļāļąāļšāļœāļđāđ‰āđāļ•āđˆāļ‡

Antonio C. Bianco, MD, is professor of medicine and a member of the Committee on Molecular Metabolism and Nutrition at the University of Chicago, where he runs a laboratory funded by the National Institutes of Health to study thyroid hormones. Bianco is also a former president of the American Thyroid Association.

āđƒāļŦāđ‰āļ„āļ°āđāļ™āļ™āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļŠāļĩāļĒāļ‡āļ™āļĩāđ‰

āđāļŠāļ”āļ‡āļ„āļ§āļēāļĄāđ€āļŦāđ‡āļ™āļ‚āļ­āļ‡āļ„āļļāļ“āđƒāļŦāđ‰āđ€āļĢāļēāļĢāļąāļšāļĢāļđāđ‰

āļ‚āđ‰āļ­āļĄāļđāļĨāļāļēāļĢāļŸāļąāļ‡

āļŠāļĄāļēāļĢāđŒāļ—āđ‚āļŸāļ™āđāļĨāļ°āđāļ—āđ‡āļšāđ€āļĨāđ‡āļ•
āļ•āļīāļ”āļ•āļąāđ‰āļ‡āđāļ­āļ› Google Play Books āļŠāļģāļŦāļĢāļąāļš Android āđāļĨāļ° iPad/iPhone āđāļ­āļ›āļˆāļ°āļ‹āļīāļ‡āļ„āđŒāđ‚āļ”āļĒāļ­āļąāļ•āđ‚āļ™āļĄāļąāļ•āļīāļāļąāļšāļšāļąāļāļŠāļĩāļ‚āļ­āļ‡āļ„āļļāļ“ āđāļĨāļ°āļŠāđˆāļ§āļĒāđƒāļŦāđ‰āļ„āļļāļ“āļ­āđˆāļēāļ™āđāļšāļšāļ­āļ­āļ™āđ„āļĨāļ™āđŒāļŦāļĢāļ·āļ­āļ­āļ­āļŸāđ„āļĨāļ™āđŒāđ„āļ”āđ‰āļ—āļļāļāļ—āļĩāđˆ
āđāļĨāđ‡āļ›āļ—āđ‡āļ­āļ›āđāļĨāļ°āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒ
āļ„āļļāļ“āļŠāļēāļĄāļēāļĢāļ–āļ­āđˆāļēāļ™āļŦāļ™āļąāļ‡āļŠāļ·āļ­āļ—āļĩāđˆāļ‹āļ·āđ‰āļ­āļˆāļēāļ Google Play āđ‚āļ”āļĒāđƒāļŠāđ‰āđ€āļ§āđ‡āļšāđ€āļšāļĢāļēāļ§āđŒāđ€āļ‹āļ­āļĢāđŒāļšāļ™āļ„āļ­āļĄāļžāļīāļ§āđ€āļ•āļ­āļĢāđŒāļ‚āļ­āļ‡āļ„āļļāļ“

āļŦāļ™āļąāļ‡āļŠāļ·āļ­āđ€āļŠāļĩāļĒāļ‡āļ—āļĩāđˆāļ„āļĨāđ‰āļēāļĒāļāļąāļ™

āļšāļĢāļĢāļĒāļēāļĒāđ‚āļ”āļĒ Mason